

November 12, 2018

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI - 400 051</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI - 400 001</b>
<b>Company Code No. AUOPHARMA</b>	<b>Company Code No. 524804</b>

Dear Sir,

**Sub: Outcome of the Board Meeting held on 12<sup>th</sup> November, 2018.**

The Board of Directors of the Company at its meeting held on 12<sup>th</sup> November, 2018 has inter alia, transacted the following business:

1. Approved the Un-audited Financial Results of the Company for the second Quarter and half year ended 30<sup>th</sup> September, 2018 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results of the Company along with the Limited Review Reports of the Statutory Auditors of the Company.
2. Approved Interim Dividend @125% i.e Rs.1.25/- (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2018-19. The Company has fixed **22<sup>nd</sup> November, 2018 as the Record Date** for the purpose of payment of Interim Dividend and the same will be paid on or before 30<sup>th</sup> November, 2018.
3. Our wholly owned subsidiary, Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire a product under development and related assets from 'Advent Pharmaceuticals Pty Ltd., Australia, through AuroScience Pty Limited, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as '**Annexure A**'.

The Board meeting commenced at 4.00 p.m and concluded at 6.30 p.m.

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**



**B. Adi Reddy**  
**Company Secretary**



Enclosures: as above.

**Annexure - A**

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.	<p><b>Name of the Target :</b> Acquisition of certain R &amp; D assets from Advent Pharmaceuticals Pty Ltd., Australia, which is into the business of R &amp; D in complex specialty generics.</p> <p>No revenues generated during 12 months period ending September 2018, since it is engaged in R &amp; D Activity.</p>
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length"	<p>Advent Pharmaceuticals Pty Ltd. is an independent company registered in Australia.</p> <p>The promoter/ promoter group/ group companies of Aurobindo Pharma Limited have no interest in the Target so the acquisition would not fall within related party transaction(s).</p>
c) Industry to which the entity being acquired belongs;	Pharmaceuticals – R & D in Complex Specialty Generics
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<ul style="list-style-type: none"> <li>▪ Acquisition provides an opportunity to acquire assets that would be used for specialty generics business.</li> <li>▪ Acquisition will lead to enhancement of R &amp; D capabilities in complex specialty generics</li> <li>▪ No sales for first 12 months is expected</li> </ul>
e) Brief details of any governmental or regulatory approvals required for the acquisition;	Closing of the transaction is subject to clearance from State Authority for Licensing.
f) Indicative time period for completion of the acquisition	January 2019
g) Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
h) Cost of acquisition or the price at which the shares are acquired	USD 12.5 million.
i) Percentage of shareholding / control acquired and / or number of shares acquired	<p>No shares were acquired.</p> <p>The Company acquires a product under development and its related assets that are being used for R &amp; D in specialty generics through AuroScience Pty Limited, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of Aurobindo Pharma Limited, India.</p>
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>The acquisition is a product under development and certain related business assets from Advent Pharmaceuticals Pty Ltd.</p> <p>There was no sale during the last three years.</p>



(CIN : L24239TG1986PLC015190)

**AUROBINDO PHARMA LIMITED**

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No. 11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)